A meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those without by Kroger, Wendy et al.
RESEARCH ARTICLE Open Access
A meta-analysis of public microarray data
identifies gene regulatory pathways
deregulated in peripheral blood
mononuclear cells from individuals with
Systemic Lupus Erythematosus compared
to those without
Wendy Kröger*, Darlington Mapiye, Jean-Baka Domelevo Entfellner and Nicki Tiffin
Abstract
Background: Systemic Lupus Erythematosus (SLE) is a complex, multi-systemic, autoimmune disease for which the
underlying aetiological mechanisms are poorly understood. The genetic and molecular processes underlying lupus
have been extensively investigated using a variety of -omics approaches, including genome-wide association studies,
candidate gene studies and microarray experiments of differential gene expression in lupus samples compared to
controls.
Methods: This study analyses a combination of existing microarray data sets to identify differentially regulated genetic
pathways that are dysregulated in human peripheral blood mononuclear cells from SLE patients compared to unaffected
controls. Two statistical approaches, quantile discretisation and scaling, are used to combine publicly available expression
microarray datasets and perform a meta-analysis of differentially expressed genes.
Results: Differentially expressed genes implicated in interferon signaling were identified by the meta-analysis,
in agreement with the findings of the individual studies that generated the datasets used. In contrast to the
individual studies, however, the meta-analysis and subsequent pathway analysis additionally highlighted TLR
signaling, oxidative phosphorylation and diapedesis and adhesion regulatory networks as being differentially
regulated in peripheral blood mononuclear cells (PBMCs) from SLE patients compared to controls.
Conclusion: Our analysis demonstrates that it is possible to derive additional information from publicly
available expression data using meta-analysis techniques, which is particularly relevant to research into rare
diseases where sample numbers can be limiting.
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Background
Systemic Lupus Erythematosus (SLE) is a multi-systemic
autoimmune disease associated with high morbidity and
mortality. At least nine out of ten lupus patients are female,
with an onset age of between late teens and early forties.
There is a significant difference in the prevalence of SLE
occurring in different population and ethnic groups, and an
occurrence of approximately 40 versus over 200 cases out
of 100 000 persons among Northern European or black
people respectively, has been reported [1, 2].
There is no predictable course for SLE, and patients
can experience alternating periods of disease flare of
varying severity; and remission, during which they have
no obvious signs or symptoms. Lupus is also commonly
misdiagnosed as it displays a broad range of clinical
presentation resulting from inflammation and damage
caused by the deposition of autoantibody-complexes in
various tissues [3]. There is a wide variety of contribut-
ing factors attributed to the active disease phenotype
and the precise pathological mechanisms of SLE have
not yet been fully elucidated. Extensive work, however,
has shown its aetiology to be multifactorial, with strong
evidence indicating a substantial genetic component to
SLE [4–9]. Lupus is now believed to be the result of a
complex model in which multiple genes influence the
likelihood of establishing the disease state in response to
different environmental triggers [10]. The molecular
basis underpinning this disease remains unclear, how-
ever, and more research is required to understand the
mechanisms contributing to the lupus phenotype.
The genetic and molecular processes underlying lupus
have been extensively investigated using a variety of
-omics approaches, including genome-wide association
studies, candidate gene studies and microarray experi-
ments of differential gene expression in lupus samples
compared to controls. Many of these data sets are in
the public domain, and can be accessed freely by re-
searchers [11–31]. These studies produce extensive and
information-rich data sets that represent a snapshot of
all genetic and/or molecular events occurring in a dis-
eased cell at one particular point in time, and can be
used to generate hypotheses on the molecular mecha-
nisms underlying lupus.
The comparison and meta-analysis of such clinical data-
sets can be complicated by a variety of factors. Firstly, and
especially with rare diseases such as SLE, sample size can
be limiting both in the number of samples included in
datasets and the number datasets within the public
domain. Secondly, because participants in the study are
usually in clinical care, it is often not possible to stratify
cohorts by treatment regimes, particular clinical symp-
toms or participant demographics, and matched con-
trols are often not available. Thirdly, the study design,
participant inclusion criteria and sample type analysed are
generally not standardised across studies. The wealth of
information contained within these data sets is frequently
underestimated, and often under-utilised once initial ana-
lyses have been completed.
In this study, we have aimed to address some of these
factors by using an approach that focuses on identifying
mechanistic pathways that may underlie SLE aetiology,
rather than focusing on the identification of key individ-
ual genes. The benefits of addressing differential changes
at a pathway level as opposed to a gene level have previ-
ously been described [32, 33]. We have analysed existing
microarray data sets to identify regulatory networks and
pathways that are dysregulated in SLE, including path-
ways that were not identified in the original individual
studies. This is achieved using statistical approaches for
meta-analysis of the combined results; using data from a
variety of microarray expression experiments performed
using different microarray platforms. We have conducted
the analysis on the premise that not all genes in an
aetiological pathway will necessarily show high levels of
differential regulation; but that many genes of that path-
way will be differentially regulated to some significant and
detectable level. Our approach, therefore, uses less strin-
gent criteria to select the differentially expressed gene lists
followed by further more stringent pathway analysis. The
first statistical approach to select differentially expressed
genes is a binning method using quantile discretisation,
and can analyse microarray datasets from different plat-
forms; and the second independent method used to
corroborate these results uses a classical scaled approach.
Our analysis demonstrates that it is possible to derive
additional aetiological pathway information from pub-
licly available expression data, using these meta-analysis
techniques. This is particularly relevant to research into
rare diseases where datasets tend to be fairly small,
potentially limiting the statistical significance of findings
from individual studies. Furthermore, this study high-
lights the value of sharing datasets in the public domain
once primary analyses are completed.
Methods
Inclusion-exclusion criteria for datasets
Microarray studies investigating human peripheral blood
mononuclear cells (PBMCs) or any subpopulation thereof
(lymphocytes, monocytes or granulocytes) in at least four
patients with SLE over the age of 16 were considered. SLE
diagnosis satisfied the criteria set by the American College
of Rheumatology [34] or similar. As we were particularly
interested in genes differentially expressed during disease
flare, lupus patients with disease activity scores of SLE
Disease Activity Index (SLEDAI; [35, 36]) less than 6, or
British Isles Lupus Assessment Group (BILAG) C, D or E
[37, 38] were excluded. Patients on maintenance immuno-
suppressive treatment but still exhibiting an active disease
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phenotype (SLEDAI ≥ 6 and/or BILAG A or B) were in-
cluded in the study. Samples that were cultured in any
way after collection were excluded. Where only subsets of
participants satisfying these criteria were identified, the
data for these individuals were included in the analysis.
Data collection and pre-processing
The ArrayExpress database [29] was used to identify
microarray studies investigating participants with SLE
compared to healthy controls. The search term used was
“systemic lupus” and results were filtered by organism
(Homo sapiens) and experiment type (RNA array assay),
in April 2013.
Raw data for Affymetrix data sets [GEO:GSE11909]
[16], [GEO:GSE13887] [17] and [GEO:GSE38351] [39]
were obtained from Gene Expression Omnibus (GEO;
[40]) using the R package GEOquery [41]. Samples
fulfilling the specified criteria were Robust-Multi array
Average normalised (Irizarry et al., 2003) using the
simpleaffy R package [42, 43]. Another study using a
custom spotted oligonucleotide array, [ArrayExpress:E-
MTAB-145] [26], was also included. These raw data
were imported into R using the ArrayExpress package
[44], and the Limma package [45] was used for both
print-tip loess within-array and quantile between-array
normalisations of samples fulfilling the above criteria
from E-MTAB-145.
Microarray probe identifiers (IDs) were converted to
Ensemble IDs with a Python script accessing the Ensembl
MySQL database (Ensembl 74: December 2013; [46]).
Probe redundancy within each data set was resolved by
averaging expression values for probe sets mapping to
common Ensembl IDs and technical replicates were aver-
aged, using a Python script.
Meta- and differential expression analysis of microarray
studies
Common Ensembl IDs between data sets were normalised
across data sets using two different methods. As the aim
of this study was to identify mechanistic pathways in-
volved in lupus aetiology as opposed to individual genes,
we used a less stringent approach in the selection of genes
so as to provide a larger gene set for the pathway analysis
in which we applied more stringent selection criteria.
The first recently developed method for the meta-
analysis of micro-array data, a binning approach, was
quantile discretization [47]. This method directly inte-
grates disparate microarray data at the gene expression
level and was first described to assess the benefit of
performing supervised classification across disparate
sources of microarray data [48]. In this study, we opti-
mised this method to perform statistical differential
expression analysis with an optimum quantile discret-
isation range of 128.
In the second method a scaling approach was employed.
We centered and scaled the expression values correspond-
ing to each sample. The result of this operation was to get
a mean equal to 0 and a sample standard deviation equal
to 1 for each sample (across all genes), which tends to can-
cel out the inter-sample variations that are non significant
for the purpose of our study on the differential expression
of genes between cases and controls.
Significantly differentially expressed genes were iden-
tified using the Wilcoxon Rank Sum Test [49] with
Benjamini-Hochberg correction for multiple testing
[50]. While we were able to apply a more stringent fil-
ter of p-value < 0.05 to the scaling dataset, we needed
to relax this filter for the binning method to < 0.1 as all
of the adjusted p-values obtained from this method
were greater than 0.05.
Pathway and regulatory network analysis
Differentially expressed genes between SLE patients in
disease flare and normal controls identified through the
binning and scaling methods were investigated using
Ingenuity Pathway Analysis (IPA; [51]). The IPA meth-
odology compares proportional representation of genes
from a defined test set in a canonical pathway (a known,
well-characterised pathway), compared to the proportional
representation of the pathway genes in the entire set of
known genes. The p-value is calculated using a right-tailed
Fisher Exact test and indicates the likelihood of the path-
way association under the random model. The adjusted
Benjamini-Hochberg p-value for a 5% FDR was calculated
as 1.51 × 10−3 for the binning method and 2.3 × 10−3 for
the scaling method, and controls for errors in selecting ca-
nonical pathways from a large set of options. The most
over-represented canonical pathways enriched with differ-
entially regulated genes were identified and an analysis of
regulatory networks was undertaken. This was used to
identify key common upstream transcription factors that
may be driving cascades of differential gene regulation, as
well as to identify any key node genes that might be cru-
cial to the differential regulation of gene regulatory path-
ways and networks in the disease state.
Results
Data collection and normalisation across studies
Four studies fulfilling the inclusion-exclusion criteria
were selected for this meta-analysis study (Fig. 1).
GSE11909 contributed 15 cases (no controls) from
PBMCs [16], GSE13887 [17] contributed 4 cases (no
controls) from CD3-positive T cells [39], GSE38351
contributed 12 cases and 8 controls from monocytes,
and E-MTAB-145 contributed 13 cases and 25 controls
from PBMCs (Fig. 1, [26]). Normalised data sets
GSE11909, GSE13887, GSE38351, E-MTAB-145 each
contained 22,283, 54,675, 22,283 and 26,495 probes
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respectively. These probe sets were reduced to 14,806,
24,772, 14,806 and 17,407 genes (respectively), of which
11,933 genes (Ensembl ID) were common across all
three data sets (Fig. 1).
Meta- and differential expression analysis of microarray
studies
Two approaches were used to normalise the expression
values across data sets. The binning and scaling
methods resulted in lists of 749 (p-value < 0.1) and 597
(p-value < 0.05) differentially expressed genes respect-
ively [see Additional file 1], with 458 of these genes
common between the lists. We took the decision to use
relatively relaxed p-value cutoffs for differential
expression analysis in light of the fact that we were in-
terested in identifying mechanistic pathways underlying
lupus, rather than identifying individual key genes, and
that we were using more stringent criteria in the path-
way analysis component of the study.
Pathway and regulatory network analysis
The top overlapping canonical pathways identified by
IPA using both binning and scaling gene lists were
Agranulocyte Adhesion and Diapedesis and the Role of
Pattern Recognition Receptors in Recognition of Bacteria
and Viruses; both with p-values < 2 × 10−04 (Table 1).
Other pathways identified included Interferon Signaling,
Oxidative Phosphorylation and Toll-like Receptor
Fig. 1 Data processing methodology. Summary of processing of data sets to generate a list of common gene expression matrices for each study
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Signaling from the binning method (p-value < 7 × 10−04),
and the Role of Cytokines in Mediating Communication
between Immune Cells, the Role of Hypercytokinemia/
hyperchemokinemia in the Pathogenesis of Influenza and
Role of Macrophages and Fibroblasts and Endothelial
Cells in Rheumatoid Arthritis for the scaling method
(p-value < 2 × 10−04). Genes assigned to the pathways are
shown in Table 2. When using Benjamini-Hochberg ad-
justed p-values, the top five pathways from either method
are significant within an FDR of 5%.
From these pathways, IPA calculated the top overlap-
ping upstream regulators to be IFNL1, IFNA2, TNF and
IRF7; all with p-values < 2 × 10−13 (Table 3). Tretinoin
and IRF3 were additionally identified from the binning
and scaling methods, respectively.
Discussion
In this study, we have used publicly available microarray
datasets to detect genes that are differentially regulated
in blood cells from people with SLE when compared to
controls without SLE. By combining the data from four
separate gene expression studies in a meta-analysis, we
hoped to be able to derive additional information from
the data that possibly could not be established from
the individual studies in isolation. In general, we found
this to be the case, with confirmation of the previously
Table 1 Top canonical pathways enriched for differentially regulated genes. Top Canonical Pathways identified for the gene lists
identified through the Binning and Scaling methods of normalisation across studies
Top Canonical Pathway Binning method Scaling method
p-value Ratio p-value Ratio
Agranulocyte Adhesion and Diapedesis 1.59 × 10-05 § 19/190 (0.1)§ 1.37 × 10-04 § 15/190 (0.079)§
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 7.11 × 10-05 § 14/127 (0.11)§ 1.18 × 10-04 § 12/127 (0.094)§
Role of Cytokines in Mediating Communication between Immune Cells 2.23 × 10−03 (0.13) 1.27 × 10-05 § 9/56 (0.161)§
Role of Hypercytokinemia/Hyperchemokinemia in the Pathogenesis
of Influenza
3.24 × 10−03 (0.13) 1.8 × 10-05 § 8/45 (0.178)§
Interferon Signaling 9.58 × 10-05 § 7/34 (0.206) § 2.14 × 10−04 0.18
Oxidative Phosphorylation 1.4 × 10-04 § 13/119 (0.109) § 0.197 0.042
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 1.10 × 10−03 0.07 1.45 × 10-04 § 20/304 (0.066)§
Toll-like Receptor Signaling 6.67 × 10-04 § 9/74 (0.122) § 3.02 × 10−03 0.095
§indicates the top five pathways for each method; the ratio represents the number of involved genes divided by the total number of genes in the pathway; the
p-value indicates over-representation of genes in the pathway
Table 2 Genes implicated in the top canonical pathways (HUGO gene symbols)
Pathway Binning Method Scaling Method
Agranulocyte Adhesion
and Diapedesis
ICAM2,PF4, MYH1, CLDN4, HRH1, MYH10, CCL1, CLDN1,
IL37, CCL19, ITGA1, IL1A, AOC3, MYH8, CCL17, IL36G, MMP1,
MYH13, MMP16
ICAM2, PF4, MYH1, MYH2, CLDN4, CCL1, CLDN1, IL37,
CCL19, ITGA1, MYH8, IL36G, MYH13, IL33, MMP16
Role of Pattern Recognition
Receptors in Recognition of
Bacteria and Viruses
OAS1, IL3, NOD1, OAS2, DDX58, NFKB2, IL11, TLR3,
IFNA1/IFNA13, OAS3, IL1A, IL5, CNTF, PRKD1
MBL2, OAS1, IL2, IL3, IL11, TLR3, IFNA1/IFNA13, OAS3,
OAS2, IL12B, DDX58, PRKD1
Role of Cytokines in Mediating
Communication between
Immune Cells
IL3, IL15, IFNA1/IFNA13, IL1A, IL5, IL36G, IL37 IL2, IL3, IL15, IFNA1/IFNA13, IL12B, IL36G, IFNA2,
IL33, IL37
Role of Hypercytokinemia/
Hyperchemokinemia in the
Pathogenesis of Influenza
IL15, CCR1, IFNA1/IFNA13, IL1A, IL36G, IL37 IL15, CCR1, IFNA1/IFNA13, IL12B, IL36G, IFNA2, IL33, IL37
Interferon Signaling OAS1, IRF9, IFIT1, IFNA1/IFNA13, IFIT3, IFITM2, MX1 OAS1, IFIT1, IFNA1/IFNA13, IFIT3, IFITM2, MX1
Oxidative Phosphorylation CYCS, UQCR11, NDUFS1, COX6B1, ATP5G2, NDUFA9,
NDUFA7, COX6A1, NDUFS5, ATP5H, NDUFB1, ATP5C1,
ATPAF2
COX6B1, NDUFA7, COX6A1, ATPAF2, NDUFS1
Role of Macrophages,
Fibroblasts and Endothelial
Cells in Rheumatoid Arthritis
IRAK1, IL15, WNT7B, CHP1, SFRP1, DKK1, TRADD, FZD7,
IL37, FZD5, IRAK4, WNT2B, PRSS1, TLR3, CCND1, IL1A,
PRKD1, WIF1, IL36G, MMP1, FCGR3A/FCGR3B
IL15, TNFSF11, WNT7B, CHP1, DKK2, SFRP1, DKK1,
TRADD, FZD7, IL37, FZD5, IRAK4, PRSS1, TLR3, CCND1,
PRKD1, WIF1, IL36G, IL33, FCGR3A/FCGR3B
Toll-like Receptor Signaling NFKB2, IRAK1, TNFAIP3, TLR3, IL1A, TAB2, IL36G, IL37,
IRAK4
TNFAIP3, TLR3, IL12B, IL36G, IL33, IL37, IRAK4
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reported findings of the separate studies; as well as some
additional insights that were not reported in the individual
papers. Despite the lack of control samples from two of the
studies, the results of the meta-analysis do not seem to be
biased towards the studies which included controls, as evi-
denced by identification of Toll-like Receptor Signaling and
Oxidative Phosphorylation which were not identified in
those original individual studies that contained controls.
Although the ideal scenario would be an equal number of
cases and controls where possible, using the combined
meta-analysis approach and increasing the number of
datasets for cases can still lead to detecting smaller
effect sizes with accuracy even in the absence of a con-
comitant increase in number of control samples. A
potential source of bias in this meta-analysis is the lack
of controls for two of the studies, and because the study
analyses previously published data this lack of controls
for two studies cannot be addressed retrospectively.
Whilst the meta-analysis including all studies increases
sample size and statistical power, and the analysis is
designed to control for false positives, we acknowledge
that it is not possible to completely rule out the possi-
bility of such bias. In particular, we focused our analysis
on identifying aetiological pathways rather than specific
aetiological genes, with inclusive criteria when selecting
differentially regulated genes. The rationale behind this
decision was two-fold: firstly, we aimed to select path-
ways for which a large proportion of genes are differen-
tially regulated in preference to pathways where fewer
genes are consistently subject to large fold changes in
expression; and secondly, we aimed to accommodate
the different characteristics and small sample sizes of
the datasets used.
Activation of the interferon (IFN) pathway in lupus
patients is well established [52], and is the common
underlying theme found in all of the original individual
studies used in this meta-analysis [16, 17, 26, 39], as well
as in other similar meta-analysis studies of lupus data
[53, 54]. In this meta-analysis, we similarly found that
when using both the binning and scaling methods, IFN
signaling was a top canonical pathway activated in lupus
patients compared to controls (Table 1), providing a
good positive control for our meta-analysis, and corrob-
orating the findings of the individual analyses. Differen-
tially regulated genes that are either integral to IFN
signaling or lie directly downstream to the IFN pathways
are shown in Fig. 2.
The IFN family of signaling proteins is a subset of cyto-
kines with a protective function elicited in response to
pathogenic species, such as bacteria or viruses. In lupus
patients, type 1 IFN signaling stimulates persistent den-
dritic cell activation and has direct effects on B and T cell
activation. Dendritic cells are able to selectively activate
autoreactive T cells, while activated B cells seem to play a
role in elevated autoantibody production and immune
complex manifestation [55]. The presence of pathogens
also stimulates elevation of other cytokines that signal im-
mune cells to migrate to places of infection. These acti-
vated immune cells are in turn stimulated to produce
more cytokines thereby creating a positive feedback loop.
In normal healthy individuals, this process is tightly con-
trolled. However deregulation of this control, sometimes
present in patients with rheumatic diseases, can lead to
cytokine storm, or hypercytokinemia: a potentially fatal
complication that can lead to severe tissue and organ
damage. Interestingly, while hypercytokinemia is quite
rarely found in adult lupus patients [56], it has been more
commonly reported in juveniles with this disease [57].
While our selection criteria only included individuals of
over 16 years of age, the study by Chaussabel et al., was in
fact on a group of pediatric lupus patients, of which we in-
cluded 15 individuals over 16 years in our meta-analysis
[16]. This may have enriched the set of differentially regu-
lated genes that we identified here for IFN signaling events
that are implicated in hypercytokinemia.
In addition, however, our study of the combined data
identified a number of other differentially regulated
pathways in lupus patients compared to controls.
Of particular interest, was the detection of activated
toll-like receptor (TLR) signaling (Table 1) and the role of
pattern recognition receptors (PRRs) in recognition of bac-
teria and viruses. Importantly, the latter pathway was a
similar result to Makashir et al.’s findings of enrichment of
genes within the module of immune defense against extra-
cellular organisms [54]. This highlights the benefits of
using multiple methodologies to explore existing datasets,
as different analytical approaches may bring a variety of
evidences together towards the same conclusions. The
TLR class of proteins, a subset of PRRs, has an essential
role in the mammalian innate immune response [58].
Along with other PRRs, these proteins are able to recog-
nise structurally conserved microbial molecular patterns,
Table 3 Top upstream regulators for differentially regulated
genes. Top upstream regulators, shown by HUGO gene
symbols, identified by IPA for the gene lists identified through
the Binning and Scaling methods of normalisation across
studies
Top Upstream
Regulators
p-value
Binning method Scaling method
IFNL1 2.20 × 10−21 4.06 × 10−21
IFNA2 1.87 × 10−20 3.13 × 10−18
Tretinoin 2.55 × 10−17 1.70 × 10-11 ¥
TNF 4.33 × 10−14 8.91 × 10−13
IRF7 5.85 × 10−14 1.40 × 10−13
IRF3 1.99 × 10-8 ¥ 1.24 × 10−12
¥indicates p-values that do not fall in the top five
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also known as pathogen-associated molecular patterns
(PAMPs). Activation of TLRs leads to a complex re-
sponse which involves activation of IFN signaling and
can have downstream roles in both apoptosis and au-
tophagy [59]. While none of the original studies
highlighted a change in this pathway for any of the
naive patient samples, Smiljanovic et al. (2012) report
TLR2 to be up-regulated in their tumor necrosis factor
(TNF)-α in vitro-treated lupus monocytes compared to
controls [39]. Furthermore, polymorphisms in TLR3,
Fig. 2 Lupus interferon model. Proposed model for differentially expressed genes found in lupus patients that are either integral to interferon signaling or
factors that lie directly downstream of interferon pathways
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TLR7 and TLR9 genes have been associated with lupus
patients in some populations [60–62] and a number of in
vivo and in vitro studies have strongly implicated a num-
ber of TLRs to play a role in the pathogenesis of lupus
[58]. By combining the datasets from the individual micro-
array studies here, we have similarly identified TLR signal-
ing as a key regulatory mechanism that is differentially
regulated in the PBMCs from lupus patients when com-
pared to unaffected controls; and have demonstrated con-
sistent differential regulation of TLR3.
Oxidative phosphorylation was another key pathway
highlighted in our meta-analysis. This is a metabolic
process through which ATP is produced by the release of
energy from a series of redox reactions. These reactions
involve the transfer of electrons between donor and ac-
ceptor pairs, performed by a group of protein complexes
situated within the mitochondrial membrane. Simultan-
eously, this electron transport chain is coupled with the
transport of protons across the membrane, setting up an
electrochemical gradient within the inter-membrane
space. ATP synthase is then able to exploit this gradient
through chemiosmosis, allowing the phosphorylation of
ADP, to produce ATP. Gene expression analysis by Fer-
nandez et al., (2009) found increases in mitochondrial
mass and membrane potential, as well as enhanced levels
of NO production and intracellular calcium in lupus sam-
ples compared to controls. They also showed that the
mammalian target of rapamycin (mTOR) activity is in-
creased in this disease. mTOR is situated on the external
mitochondrial membrane, and plays an essential role
in the oxidative capacity of mitochondria, and pharma-
cological inhibition of mTOR by rapamycin has been
shown to reduce the ATP generating capacity of mito-
chondria [63, 64]. Moreover, oxidative stress is known
to be increased in lupus patients compared to healthy
controls [65], and a number of oxidative stresses have
been shown to influence oxidative phosphorylation
[66, 67]. Taken together, it is likely that there will be
an intimate interplay of changes in lupus patients be-
tween these processes and oxidative phosphorylation.
Our meta-analysis has highlighted components of this
pathway as being differentially regulated in PBMCs
from lupus patients, suggesting that further research to
explore a role for oxidative phosphorylation in SLE
pathogenesis is warranted.
Diapedesis, or leukocyte extravasation, is the movement
of white blood cells out of the vascular system via intact
vessel walls into adjacent inflammation-affected tissue. As
inflammation is a highly common disease manifestation
found in lupus patients, it is reasonable to assume that
diapedesis signaling will be markedly deregulated in lupus
patients. This is further supported by the findings of
Makashir et al., 2015 reporting an enrichment of genes in-
volved in wounding and leukocyte cell migration modules
within lupus patients, and importantly, both studies
similarly identified FCGR3B as a key player within the
associated pathway [54]. Together with ITGB2, ITGAM
forms the Macrophage-1 antigen (Mac-1) integrin or
complement receptor 3 (CR3), known to be involved in
leukocyte extravasation and phagocytosis. Notably, a
number of polymorphisms within or near the gene en-
coding Integrin alpha M, or ITGAM, have been highly
associated with genetic lupus risk factors, with the
rs1143679 variant resulting in an R77H substitution in
its gene product [68–71]. Interestingly, cells transfected
with this mutant showed reduced ligand (ICAM-1 and
ICAM-2) and complement (iC3b) binding abilities well
as impaired iC3b-mediated phagocytosis, compared to
those transfected with wild type ITGAM [72]. Rhodes
and co-workers confirmed most of these results in ex
vivo monocytes (adhesion) and macrophages (phagocyt-
osis) from wild type or R77H homozygous volunteers,
and also reported reduced adhesion to fibrinogen and
DC-SIGN, the dendritic cell-specific intercellular adhe-
sion molecule-3Grabbing non-integrin receptor, in
R77H homozygous monocytes [73]. More recently,
Fossati-Jimack and co-workers provided strong evi-
dence suggesting that this variant’s role in lupus sus-
ceptibility is most likely due to its effects on clearance
of cellular debris. They were only able to corroborate
findings of reduced iC3b-directed phagocytosis in
monocytes, macrophages, neutrophils and dendritic
cells heterozygous for the R77H/R allele; the genotype
most commonly associated with lupus disease [74]. The
dysregulation of these key functions of diapedesis and
adhesion, detected in our study through differential
expression of key molecules in PBMCs from SLE
patients, may therefore be contributing to pathogenic
mechanisms in SLE.
From the gene lists in Table 2, it can be seen that
there is frequent overlap in gene membership between
the different pathways identified. This reflects the
strong interplay that exists between the pathway func-
tions and regulatory mechanisms that drive dysregu-
lated cellular mechanisms; and is consistent with the
complexity of SLE aetiology whereby multiple down-
stream effects of gene dysregulation can result in the
complex disease phenotype. Identification of common
upstream regulators of these pathways, however, may
provide insights into key molecules that are fundamen-
tal to the dysregulated cellular processes underlying
SLE aetiology.
IFN-lambda 1 (IFNL1, also known as IL29), a type III
IFN, has been proposed previously as a key molecule in
renal disorder and arthritic progression in SLE [75]. The
role of IFN alpha in SLE has been extensively explored
(reviewed in [76]), and IFN-alpha 2 (IFNA2) has recently
been implicated in perpetuation of SLE disease activity
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[77]. Furthermore, a number of members highlighted
within the IFN pathway in this study have previously been
reported in other meta-analyses, including IFIT1, IFIT3,
MX1, IRF7 and OAS1 [53, 54]. TNF is already targeted by
biologic therapeutic approaches [78], and IFN regulatory
factors 3 and 7 (IRF3 and IRF7) have been implicated in
the IFN signature in lupus previously [54, 79, 80]. Whilst
pathway analysis highlighted tretinoin as a common up-
stream regulator of identified pathways, there is little in-
formation about a role for tretinoin, belonging to the
family of retinoids, in SLE. Whilst some studies describe
the use of retinoids for topical treatment of cutaneous
lupus, for example [81]; and a case study describes the use
of retinoids in treating patients with lupus nephritis [82];
any relationship that may exist between this molecule and
SLE progression is, as yet, unclear.
It is important to remember that the cellular compos-
ition of PBMCs can change in the lupus disease state, with
increases in myeloid and decreases in lymphoid lineages
observed in lupus PBMCs compared to control samples.
These changes can also bring about differences observed
in gene regulation [26], depending on the cell population
that is assayed. With this in mind, we are aware that the
inclusion of specific monocyte and T cell subsets within
our PBMC meta-analysis may bias the end result because
of exclusion of the other cell types in generating these
datasets. We think it is likely, however, that this bias
would be most likely to dilute the observed differential ex-
pression between disease state and controls; rather than
enriching a signal from the selected cell types. If this were
the case, this would tend to result in concealment of a
gene signature of interest, rather than indicating false
positive differential regulation that does not occur in all
datasets.
Conclusions
This study demonstrates the value that can be gained from
using appropriate statistical methods to combine expres-
sion datasets from multiple studies that compare gene ex-
pression between PBMCs from SLE patients compared to
controls. The methods used here are robust even across
different microarray platforms, and the pathways that are
enriched for differentially regulated gene expression are
consistent with the primary findings of the individual
studies. Furthermore, the meta-analysis of multiple data-
sets has detected gene expression signatures additional to
those described by the individual studies; and these regu-
latory pathways have been implicated in SLE through
independent research approaches, confirming the validity
of this meta-analysis. It is likely that the knowledgebase of
regulatory pathways has been expanded since the individ-
ual studies were undertaken, and this may contribute in
part to the increased range of regulatory mechanisms that
were identified by the current meta-analysis. This further
indicates the value in revisiting earlier datasets to extract
more information about molecular processes underlying
the disease state.
Such approaches may have particular value in the study
of rare diseases, where study size can be limiting; and also
where available datasets are clinically heterogeneous and
cannot be stratified by stringent clinical or sampling
criteria. Whilst bioinformatics analyses of existing datasets
are currently unlikely to provide unequivocal clinical an-
swers to disease aetiology, we believe that expanding the
range of methodologies to explore such datasets can iden-
tify new mechanistic pathways to explore in ongoing and
future research. Such studies highlight the utility of con-
trolled public access to existing datasets, where ethical
requirements for data re-use can be met, in order to
increase our understanding of molecular mechanisms
contributing to the aetiology of rare diseases.
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